Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7142354 | 0.98 | HDAC8 (0.68) | PDE4BHDAC8HDAC1MAPTNPC1 | |
| SCHEMBL319315 | 0.95 | PDE4B (0.70) | PDE4BHDAC8HDAC1MAPTNPC1 | |
| SCHEMBL3171960 | 0.91 | PDE4B (0.79) | PDE4BHDAC8HDAC1MAPTNPC1 | |
| SCHEMBL2336836 | 0.87 | MAPT (0.66) | PDE4BHDAC8HDAC1MAPTNPC1 | |
| SCHEMBL4082864 | 0.87 | PDE4B (0.86) | PDE4BHDAC8HDAC1MAPTNPC1 | |
| SCHEMBL8570532 | 0.86 | CYP1A2 (0.67) | PDE4BHDAC8HDAC1MAPTNPC1 | |
| SCHEMBL1304627 | 0.84 | PDE4B (0.70) | PDE4BHDAC8HDAC1MAPTNPC1 | |
| SCHEMBL7923588 | 0.84 | PDE4B (0.70) | PDE4BHDAC8HDAC1MAPTNPC1 | |
| SCHEMBL7928597 | 0.84 | PDE4B (0.70) | PDE4BHDAC8HDAC1MAPTNPC1 | |
| SCHEMBL2413943 | 0.84 | PDE4B (0.93) | PDE4BHDAC8HDAC1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210524-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210524-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210524-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-08-19 | — | — | US | disclosed |
| WO-2009012954-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2009-01-29 | — | — | WO | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ISHIHARA YUJI | 2006-09-21 | — | — | US | disclosed |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-08 | — | — | US | disclosed |
| EP-1466625-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| EP-1140895-B1 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-03-24 | — | — | EP | disclosed |
| EP-1140895-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | disclosed |
| US-6087346-A | Sigma receptor ligands and the use thereof | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-07-11 | — | — | US | disclosed |
| EP-0714292-A4 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | CAMBRIDGE NEUROSCIENCE INC (US) | 1996-10-09 | — | — | EP | disclosed |
| EP-0714292-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1996-06-05 | — | — | EP | disclosed |
| WO-1995000131-A1 | SIGMA RECEPTOR LIGANDS AND THE USE THEREOF | CAMBRIDGE NEUROSCIENCE, INCORPORATED (US) | 1995-01-05 | — | — | WO | disclosed |
| US-3946022-A | ANTIHISTAMINES, ANTIALLERGENS, BRONCHODILATORS | RICHARDSON-MERRELL INC. (US) | 1976-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210524-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, ESR2 | PDE4B 2527/4885HDAC8 854/4885HDAC1 1130/4885 |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | PDE4B 209/4885HDAC8 1946/4885HDAC1 1053/4885 |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, ACE | PDE4B 270/4885HDAC8 1655/4885HDAC1 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.